Erratum to “Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites” (International Journal for Parasitology: Drugs and Drug Resistance (2015) 5 (117–126)(S2211320715000123)(10.1016/j.ijpddr.2015.05.004));Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 5, Issue 3, 2015, Pages 117-126

  Engel, Jessica A ^a   Jones, Amy J ^a   Avery, Vicky M ^a   Sumanadasa, Subathdrage D M ^a   Ng, Susanna S ^a   Fairlie, David P ^b   Adams, Tina S ^a   Andrews, Katherine T ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

African sleeping sickness; HDAC inhibitors; Histone; Malaria; Plasmodium falciparum; Trypanosoma brucei

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; CHLOROQUINE; DIMINAZENE ACETURATE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PANOBINOSTAT; PENTAMIDINE; ROMIDEPSIN; VORINOSTAT; ANTIPROTOZOAL AGENT;

ANTIPROLIFERATIVE ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; ASEXUAL REPRODUCTION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HISTONE ACETYLATION; IC50; IN VITRO STUDY; MALARIA; MALARIA FALCIPARUM; MAMMAL CELL; MULTIPLE MYELOMA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T CELL LYMPHOMA; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS; CELL CULTURE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; HEK293 CELL LINE; HUMAN; PARASITOLOGY; TRYPANOSOMA;

ANTIPROTOZOAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; ERYTHROCYTES; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; TRYPANOSOMA; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84934754881     PISSN: None     EISSN: 22113207     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2016.05.001     Document Type: Erratum

References (69)

1. Alonso V.L., Serra E.C. Lysine acetylation: elucidating the components of an emerging global signaling pathway in trypanosomes. J.Biomed. Biotechnol. 2012, 2012:452934.
2. Alsford S., Horn D. Trypanosomatid histones. Mol. Microbiol. 2004, 53:365-372.
3. Andrews K.T., Fisher G., Skinner-Adams T.S. Drug repurposing and human parasitic protozoan diseases. Int. J. Parasitol.-Drugs Drug Resist. 2014, 4:95-111.
4. Andrews K.T., Haque A., Jones M.K. HDAC inhibitors in parasitic diseases. Immunol. Cell. Biol. 2012, 90:66-77.
5. Andrews K.T., Tran T.N., Fairlie D.P. Towards histone deacetylase inhibitors as new antimalarial drugs. Curr. Pharm. Des. 2012, 18:3467-3479.
6. Andrews K.T., Tran T.N., Lucke A.J., Kahnberg P., Le G.T., Boyle G.M., Gardiner D.L., Skinner-Adams T.S., Fairlie D.P. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 2008, 52:1454-1461.
7. Aurrecoechea C., Brestelli J., Brunk B.P., Dommer J., Fischer S., Gajria B., Gao X., Gingle A., Grant G., Harb O.S., Heiges M., Innamorato F., Iodice J., Kissinger J.C., Kraemer E., Li W., Miller J.A., Nayak V., Pennington C., Pinney D.F., Roos D.S., Ross C., Stoeckert C.J., Treatman C., Wang H. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 2009, 37:D539-D543.
8. Azzi A., Cosseau C., Grunau C. Schistosoma mansoni: developmental arrest of miracidia treated with histone deacetylase inhibitors. Exp. Parasitol. 2009, 121:288-291.
9. Baldi D.L., Andrews K.T., Waller R.F., Roos D.S., Howard R.F., Crabb B.S., Cowman A.F. RAP1 controls rhoptry targeting of RAP2 in the malaria parasite Plasmodium falciparum. EMBO J. 2000, 19:2435-2443.
10. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., Grever M.R. Aphase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
11. Caffrey C.R., Steverding D. Recent initiatives and strategies to developing new drugs for tropical parasitic diseases. Expert Opin. Drug Discov. 2008, 3:173-186.
12. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009, 45:787-795.
13. Carrillo A.K., Guiguemde W.A., Guy R.K. Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). Bioorg. Med. Chem. 2015, 10.1016/j.bmc.2014.12.066.
14. Coiffier B., Pro B., Prince H.M., Foss F., Sokol L., Greenwood M., Caballero D., Borchmann P., Morschhauser F., Wilhelm M., Pinter-Brown L., Padmanabhan S., Shustov A., Nichols J., Carroll S., Balser J., Balser B., Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J.Clin. Oncol. 2012, 30:631-636.
15. Coleman B.I., Skillman K.M., Jiang R.H., Childs L.M., Altenhofen L.M., Ganter M., Leung Y., Goldowitz I., Kafsack B.F., Marti M., Llinas M., Buckee C.O., Duraisingh M.T. APlasmodium falciparum histone deacetylase regulates antigenic variation and gametocyte conversion. Cell. Host Microbe 2014, 16:177-186.
16. Darkin-Rattray S.J., Gurnett A.M., Myers R.W., Dulski P.M., Crumley T.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., Singh S.B., Goetz M.A., Dombrowski A.W., Polishook J.D., Schmatz D.M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13143-13147.
17. De Ruijter A.J., Van Gennip A.H., Caron H.N., Kemp S., Van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370:737-749.
18. Dow G.S., Chen Y., Andrews K.T., Caridha D., Gerena L., Gettayacamin M., Johnson J., Li Q., Melendez V., Obaldia N., Tran T.N., Kozikowski A.P. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother. 2008, 52:3467-3477.
19. Dubois F., Caby S., Oger F., Cosseau C., Capron M., Grunau C., Dissous C., Pierce R.J. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol. Biochem. Parasitol. 2009, 168:7-15.
20. Faria J., Moraes C.B., Song R., Pascoalino B.S., Lee N., Siqueira-Neto J.L., Cruz D.J., Parkinson T., Ioset J.R., Cordeiro-Da-Silva A., Freitas-Junior L.H. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei. J.Biomol. Screen 2015, 20:70-81.
21. Freitas-Junior L.H., Hernandez-Rivas R., Ralph S.A., Montiel-Condado D., Ruvalcaba-Salazar O.K., Rojas-Meza A.P., Mancio-Silva L., Leal-Silvestre R.J., Gontijo A.M., Shorte S., Scherf A. Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell 2005, 121:25-36.
22. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., Randolph S.S., Hardwick J.S., Reilly J.F., Chen C., Ricker J.L., Secrist J.P., Richon V.M., Frankel S.R., Kantarjian H.M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
23. Garnock-Jones K.P. Panobinostat: first global approval. Drugs 2015, 75:695-704. 10.1007/s40265-015-0388-8.
24. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., Bhalla K. Aphase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2006, 12:4628-4635.
25. Grant S., Easley C., Kirkpatrick P. Vorinostat. Nat. Rev. Drug Discov. 2007, 6:21-22.
26. Hansen F.K., Skinner-Adams T.S., Duffy S., Marek L., Sumanadasa S.D., Kuna K., Held J., Avery V.M., Andrews K.T., Kurz T. Synthesis, antimalarial properties, and SAR studies of alkoxyurea-based HDAC inhibitors. ChemMedChem. 2014, 9:665-670.
27. Hansen F.K., Sumanadasa S.D., Stenzel K., Duffy S., Meister S., Marek L., Schmetter R., Kuna K., Hamacher A., Mordmuller B., Kassack M.U., Winzeler E.A., Avery V.M., Andrews K.T., Kurz T. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. Eur. J. Med. Chem. 2014, 82:204-213.
28. Ingram A.K., Horn D. Histone deacetylases in Trypanosoma brucei: two are essential and another is required for normal cell cycle progression. Mol. Microbiol. 2002, 45:89-97.
29. Jones A.J., Avery V.M. Whole-organism high-throughput screening against Trypanosoma brucei brucei. Expert Opin. Drug Discov. 2013, 8:495-507.
30. Kelly J.M., Taylor M.C., Horn D., Loza E., Kalvinsh I., Bjorkling F. Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei. Bioorg. Med. Chem. Lett. 2012, 22:1886-1890.
31. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
32. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell. Biol. 2012, 90:85-94.
33. Mai A., Cerbara I., Valente S., Massa S., Walker L.A., Tekwani B.L. Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylase inhibitors. Antimicrob. Agents Chemother. 2004, 48:1435-1436.
34. Malmquist N.A., Moss T.A., Mecheri S., Scherf A., Fuchter M.J. Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16708-16713.
35. Mandava V., Fernandez J.P., Deng H., Janzen C.J., Hake S.B., Cross G.A. Histone modifications in Trypanosoma brucei. Mol. Biochem. Parasitol. 2007, 156:41-50.
36. Mariadason J.M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008, 3:28-37.
37. Miao J., Fan Q., Cui L., Li J., Li J., Cui L. The malaria parasite Plasmodium falciparum histones: organization, expression, and acetylation. Gene 2006, 369:53-65.
38. Modesitt S.C., Sill M., Hoffman J.S., Bender D.P., Gynecologic Oncology G. Aphase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol. 2008, 109:182-186.
39. Molife L.R., Attard G., Fong P.C., Karavasilis V., Reid A.H., Patterson S., Riggs C.E., Higano C., Stadler W.M., Mcculloch W., Dearnaley D., Parker C., De Bono J.S. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 2010, 21:109-113.
40. Murray P.J., Kranz M., Ladlow M., Taylor S., Berst F., Holmes A.B., Keavey K.N., Jaxa-Chamiec A., Seale P.W., Stead P., Upton R.J., Croft S.L., Clegg W., Elsegood M.R. The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. Bioorg. Med. Chem. Lett. 2001, 11:773-776.
41. Nwaka S., Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 2006, 5:941-955.
42. Page B., Page M., Noel C. Anew fluorometric assay for cytotoxicity measurements in-vitro. Int. J. Oncol. 1993, 3:473-476.
43. Pallavi R., Roy N., Nageshan R.K., Talukdar P., Pavithra S.R., Reddy R., Venketesh S., Kumar R., Gupta A.K., Singh R.K., Yadav S.C., Tatu U. Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J.Biol. Chem. 2010, 285:37964-37975.
44. Parker J.P., Nimir H., Griffith D.M., Duff B., Chubb A.J., Brennan M.P., Morgan M.P., Egan D.A., Marmion C.J. Anovel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and invitro cytotoxicity. J.Inorg. Biochem. 2013, 124:70-77.
45. Patel V., Mazitschek R., Coleman B., Nguyen C., Urgaonkar S., Cortese J., Barker R.H., Greenberg E., Tang W., Bradner J.E., Schreiber S.L., Duraisingh M.T., Wirth D.F., Clardy J. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. J.Med. Chem. 2009, 52:2185-2187.
46. Patil V., Guerrant W., Chen P.C., Gryder B., Benicewicz D.B., Khan S.I., Tekwani B.L., Oyelere A.K. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 2010, 18:415-425.
47. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009, 5:601-612.
48. Prince H.M., Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin. Cancer Res. 2012, 18:3509-3515.
49. Rathkopf D., Wong B.Y., Ross R.W., Anand A., Tanaka E., Woo M.M., Hu J., Dzik-Jurasz A., Yang W., Scher H.I. Aphase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 2010, 66:181-189.
50. Rubin E.H., Agrawal N.G., Friedman E.J., Scott P., Mazina K.E., Sun L., Du L., Ricker J.L., Frankel S.R., Gottesdiener K.M., Wagner J.A., Iwamoto M. Astudy to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res. 2006, 12:7039-7045.
51. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., Brooks R., Piekarz R.L., Tucker E., Figg W.D., Chan K.K., Goldspiel B., Fojo A.T., Balcerzak S.P., Bates S.E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 2002, 8:718-728.
52. Sheader K., Te Vruchte D., Rudenko G. Bloodstream form-specific up-regulation of silent vsg expression sites and procyclin in Trypanosoma brucei after inhibition of DNA synthesis or DNA damage. J.Biol. Chem. 2004, 279:13363-13374.
53. Skehan P., Storeng R., Scudiero D., Monks A., Mcmahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J.Natl. Cancer Inst. 1990, 82:1107-1112.
54. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Buhl-Jensen P., Molife R., Brown R., De Bono J.S., Evans T.R. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother. Pharmacol. 2011, 67:1273-1279.
55. Stolfa D.A., Marek M., Lancelot J., Hauser A.T., Walter A., Leproult E., Melesina J., Rumpf T., Wurtz J.M., Cavarelli J., Sippl W., Pierce R.J., Romier C., Romier C., Jung M. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni. J. Mol. Biol. 2014, 426(20):3442-3453.
56. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
57. Sumanadasa S.D., Goodman C.D., Lucke A.J., Skinner-Adams T., Sahama I., Haque A., Do T.A., Mcfadden G.I., Fairlie D.P., Andrews K.T. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob. Agents Chemother. 2012, 56:3849-3856.
58. Sun W., Tanaka T.Q., Magle C.T., Huang W., Southall N., Huang R., Dehdashti S.J., Mckew J.C., Williamson K.C., Zheng W. Chemical signatures and new drug targets for gametocytocidal drug development. Sci. Rep. 2014, 4:3743.
59. Sundriyal S., Malmquist N.A., Caron J., Blundell S., Liu F., Chen X., Srimongkolpithak N., Jin J., Charman S.A., Scherf A., Fuchter M.J. Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds. ChemMedChem. 2014, 9:2360-2373.
60. Sykes M.L., Avery V.M. Development of an Alamar blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am. J. Trop. Med. Hyg. 2009, 81:665-674.
61. Thompson C.A. Belinostat approved for use in treating rare lymphoma. Am. J. Health Syst. Pharm. 2014, 71:1328.
62. Tonkin C.J., Carret C.K., Duraisingh M.T., Voss T.S., Ralph S.A., Hommel M., Duffy M.F., Silva L.M., Scherf A., Ivens A., Speed T.P., Beeson J.G., Cowman A.F. Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol. 2009, 7:e84.
63. Trenholme K., Marek L., Duffy S., Pradel G., Fisher G., Hansen F.K., Skinner-Adams T.S., Butterworth A., Ngwa C.J., Moecking J., Goodman C.D., Mcfadden G.I., Sumanadasa S.D., Fairlie D.P., Avery V.M., Kurz T., Andrews K.T. Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules. Antimicrob. Agents Chemother. 2014, 58:3666-3678.
64. Walliker D., Quakyi I.A., Wellems T.E., Mccutchan T.F., Szarfman A., London W.T., Corcoran L.M., Burkot T.R., Carter R. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 1987, 236:1661-1666.
65. Wang Q.P., Kawahara T., Horn D. Histone deacetylases play distinct roles in telomeric VSG expression site silencing in African trypanosomes. Mol. Microbiol. 2010, 77:1237-1245.
66. Wellems T.E., Oduola Ayo M.J., Fenton B., Desjardins R., Panton L.J., do Rosario V.E. Chromosome size variation occurs in cloned Plasmodium falciparum on invitro cultivation. Rev. Bras. Genet. 1988, 11:813-825.
67. WHO Global Burden of Disease: 2004 Update 2008, (Geneva).
68. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
69. Yeo W., Chung H.C., Chan S.L., Wang L.Z., Lim R., Picus J., Boyer M., Mo F.K., Koh J., Rha S.Y., Hui E.P., Jeung H.C., Roh J.K., Yu S.C., To K.F., Tao Q., Ma B.B., Chan A.W., Tong J.H., Erlichman C., Chan A.T., Goh B.C. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group. J.Clin. Oncol. 2012, 30:3361-3367.